相关实验视频

Updated: Jul 28, 2026

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on: October 27, 2014

临床研究框架关于基因代谢疗法在质母细胞瘤中的建议

Tomás Duraj¹, Miriam Kalamian², Giulio Zuccoli³

¹Biology Department, Boston College, Chestnut Hill, MA, 02467, USA. durajto@gmail.com.

|December 5, 2024

概括

在质母细胞瘤 (GBM) 中准葡萄糖和谷氨酸代谢提供了一个新的治疗策略. 类代谢疗法 (KMT) 结合饮食和药物来抑制瘤燃料,改善侵略性脑癌的结果.

科学领域:

代谢性瘤学代谢性瘤学
癌症代谢癌症代谢
神经瘤学神经瘤学

背景情况:

质母细胞瘤 (GBM) 是一种具有攻击性的脑瘤,尽管使用标准治疗方法,预后不佳.
GBM 细胞在能量和生长方面严重依赖葡萄糖和谷氨酸.
针对这些关键的新陈代谢途径提供了一个新的治疗途径.

研究的目的:

提出基于针对葡萄糖和谷氨酸代谢的GBM的共识治疗方案.
通过改变能量代谢来抑制瘤生长的策略,引入基因代谢疗法 (KMT).
为未来的代谢瘤学研究建立最佳实践.

主要方法:

同时准糖解和谷氨酸溶解以抑制GBM细胞的增殖.
使用代谢疗法 (KMT),包括饮食和药物组合.
使用葡萄糖-子指数 (GKI) 作为治疗合规性的生物标志物.
实施GKI调整的性饮食,卡路里限制和禁食.
服用代谢抑制剂以准糖分和谷氨酸溶解的流量.

主要成果:

拟议的战略旨在通过使它们缺乏必要的可发酵燃料来减少GBM细胞的增殖.
KMT将能量代谢转向治疗性症,使用非发酵燃料.
这种方法预计将在GBM和其他由糖解和谷氨酸溶解驱动的瘤中有效.
与葡萄糖和谷氨酸相比,非发酵燃料在持续的癌细胞增殖方面效率较低.

结论:

同时准糖解和谷氨酸溶解是治疗GBM的一个有希望的策略.
基因代谢疗法 (KMT) 为代谢瘤学研究提供了一个新的,基于证据的框架.
这种方法为各种癌症提供了协同的代谢原始基线.
需要进一步的研究和临床研究来验证KMT在治疗质母细胞瘤和其他恶性瘤.

关键词:

癌症癌症癌症癌症质母细胞瘤 (glioblastoma) 是一个葡萄糖氨基溶解是什么代谢过程中的代谢.精准医学是一门精准的医学.研究设计研究设计研究设计华堡效应是什么意思

更多相关视频

Generation of Microtumors Using 3D Human Biogel Culture System and Patient-derived Glioblastoma Cells for Kinomic Profiling and Drug Response Testing

Generation of Microtumors Using 3D Human Biogel Culture System and Patient-derived Glioblastoma Cells for Kinomic Profiling and Drug Response Testing

Published on: June 9, 2016

The Clinical Application of Tumor Treating Fields Therapy in Glioblastoma

The Clinical Application of Tumor Treating Fields Therapy in Glioblastoma

Published on: April 16, 2019

相关概念视频

Gene Therapy

Gene Therapy

Gene therapy is a technique where a gene is inserted into a person’s cells to prevent or treat a serious disease. The added gene may be a healthy version of the gene that is mutated in the patient, or it could be a different gene that inactivates or compensates for the patient’s disease-causing gene. For example, in patients with severe combined immunodeficiency (SCID) due to a mutation in the gene for the enzyme adenosine deaminase, a functioning version of the gene can be inserted. The...

Cancer Therapies

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...